Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiao'er Kechuan Granules is a Traditional Chinese Medicine (TCM) compound formulation primarily indicated for the treatment of pediatric respiratory ailments, including bronchitis, pneumonia, and cough variant asthma. The formulation is typically based on the classic 'Ma Xing Shi Gan Tang' framework, containing active herbal ingredients such as *Ephedra sinica* (Mahuang), *Prunus armeniaca* (Xingren), *Gypsum fibrosum* (Shigao), and *Glycyrrhiza uralensis* (Gancao), often supplemented with other herbs like *Scutellaria baicalensis* and *Aster tataricus*. It functions as a bronchodilator and anti-inflammatory agent; the ephedrine alkaloids derived from *Ephedra* act as beta-2 adrenergic agonists to relieve bronchospasm, while other components provide antitussive and expectorant effects. Beijing Huikang Century Biotechnology Consulting has been identified as a key developer or regulatory sponsor involved in clinical trials for this formulation, specifically focusing on its efficacy in treating pediatric cough variant asthma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiao'er Kechuan Granules.